Antidepressant-like activity of magnesium in the olfactory bulbectomy model is associated with the AMPA/BDNF pathway

Psychopharmacology

Volumn 232, Issue 2, 2015, Pages 355-367

  Pochwat, Bartlomiej ^a   Sowa Kucma, Magdalena ^b   Kotarska, Katarzyna ^a,c   Misztak, Paulina ^a   Nowak, Gabriel ^a,d   Szewczyk, Bernadeta ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

^b UNIVERSITY OF RZESZÓW   (Poland)

^c JAGIELLONIAN UNIVERSITY   (Poland)

^d JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

AMPA; BDNF; Depression; Glutamatergic system; Magnesium; NMDA; Olfactory bulbectomy

Indexed keywords

ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; AMPA RECEPTOR; BRAIN DERIVED NEUROTROPHIC FACTOR; GLUA1 PROTEIN; MAGNESIUM; MESSENGER RNA; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2A; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2B; UNCLASSIFIED DRUG; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; GLUTAMATE RECEPTOR IONOTROPIC, AMPA 1; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

AMYGDALOID NUCLEUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDEPRESSANT ACTIVITY; ARTICLE; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DEPRESSION; DRUG DOSE COMPARISON; HIPPOCAMPUS; HYPERACTIVITY; NONHUMAN; OLFACTORY BULBECTOMY; OPEN FIELD TEST; PASSIVE AVOIDANCE TEST; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT; ANIMAL; ANTAGONISTS AND INHIBITORS; BRAIN; DISEASE MODEL; DRUG EFFECTS; MALE; METABOLISM; OLFACTORY BULB; SPRAGUE DAWLEY RAT; SURGERY;

ALPHA-AMINO-3-HYDROXY-5-METHYL-4-ISOXAZOLEPROPIONIC ACID; AMITRIPTYLINE; ANIMALS; ANTIDEPRESSIVE AGENTS; BRAIN; BRAIN-DERIVED NEUROTROPHIC FACTOR; DEPRESSION; DISEASE MODELS, ANIMAL; MAGNESIUM; MALE; METABOLIC NETWORKS AND PATHWAYS; OLFACTORY BULB; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, AMPA; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 84926507133     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-014-3671-6     Document Type: Article

References (48)

1. Akinfiresoye L, Tizabi Y. (2013) Antidepressant effects of AMPA and ketamine combination: role of hippocampal BDNF, synapsin, and mTOR. Psychopharmacology (Berl) 230:291-298.
2. Ambrogi Lorenzini C.G., Baldi E, Bucherelli C., Sacchetti B, Tassoni G. (1997) Role of ventral hippocampus in acquisition, consolidation and retrieval of rat's passive avoidance response memory trace. Brain Res 768:242-248
3. Autry AE, Adachi M, Nosyreva E, Na ES, Los MF, Cheng P, Kavalali ET, Monteggia LM (2011) NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature 475:91-96
4. Berman RM, Cappiello A, Anand A., Oren DA, Heninger GR, Charney DS, Krystal J.H. (2000) Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 47:351-354
5. Decollogne S, Tomas A, Lecerf C., Adamowicz E, Seman M. (1997) NMDA receptor complex blockade by oral administration of magnesium: comparison with MK-801. Pharmacol Biochem Behav 58:261-268
6. Du J, Creson TK, Wu L, Ren M., Gray NA, Falke C, Wei Y, Wang Y., Blumenthal R, Machado-Vieira R, Yuan P, Chen G., Zhuo M, Manji H.K. (2008) The role of hippocampal GluR1 and GluR2 receptors in manic-like behavior. J Neurosci 28:68-79
7. Duman RS, Voleti B. (2012) Signaling pathways underlying the pathophysiology and treatment of depression: novel mechanisms for rapid-acting agents. Trends Neurosci 35:47-56
8. Duman RS, Li N, Liu R., Duric V, Aghajanian G. (2012) Signaling pathways underlying the rapid antidepressant actions of ketamine. Neuropharmacology 62:35-41
9. Feyissa AM, Chandran A, Stockmeier C.A., Karolewicz B. (2009) Reduced levels of NR2A and NR2B subunits of NMDA receptor and PSD-95 in the prefrontal cortex in major depression. Prog Neuro-Psychopharmacol Biol Psychiatry 33:70-75
10. Goosens KA, Hobin JA, Maren S. (2003) Auditory-evoked spike firing in the lateral amygdala and Pavlovian fear conditioning: mnemonic code or fear bias? Neuron 40:1013-1022
11. Harkin A, Kelly JP, Leonard B.E. (2003) A review of the relevance and validity of olfactory bulbectomy as a model of depression. Clin Neurosci Res 3:253-262
12. Hashizume N, Mori M. (1990) An analysis of hypermagnesemia and hypomagnesemia. Jpn J Med 29:368-372
13. Ho Y, Liu T, Tai M., Wen Z, Chow RS, Tsai Y, Wong C. (2001) Effects of olfactory bulbectomy on NMDA receptor density in the rat brain: [3H] MK-801 binding assay. Brain Res 900:214-218
14. Kelly JP, Wrynn AS, Leonard B.E. (1997) The olfactory bulbectomized rat as a model of depression: an update. Pharmacol Ther 74:299-316
15. Kirov GK, Birch NJ, Steadman P, Ramsey RG (1994) Plasma magnesium levels in a population of psychiatric patients: correlations with symptoms. Neuropsychobiology 30:73-78
16. LeDoux JE (2000) Emotion circuits in the brain. Annu Rev Neurosci 23: 155-184
17. Lee H, Kirkwood A. (2011) AMPA receptor regulation during synaptic plasticity in hippocampus and neocortex. Semin Cell Dev Biol 22: 514-520
18. Lee H, Takamiya K, He K., Song L, Huganir R.L. (2010) Specific roles of AMPA receptor subunit GluR1 (GluA1) phosphorylation sites in regulating synaptic plasticity in the CA1 region of hippocampus. J Neurophysiol 103:479-489
19. Li N, Lee B, Liu R., Banasr M, Dwyer JM, Iwata M, Li X., Aghajanian G, Duman R.S. (2010) mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 329: 959-964
20. Lima-Ojeda J.M., Vogt MA, Pfeiffer N, Dormann C., Köhr G, Sprengel R., Gass P, Inta D. (2013) Pharmacological blockade of GluN2B-containing NMDA receptors induces antidepressant-like effects lacking psychotomimetic action and neurotoxicity in the perinatal and adult rodent brain. Prog Neuro-Psychopharmacol Biol Psychiatry 45:28-33
21. Linder J, Brismar K, Beck-Friis J, Saaf J., Wetterberg L. (1989) Calcium and magnesium concentrations in affective disorder: difference between plasma and serum in relation to symptoms. Acta Psychiatr Scand 80:527-537
22. Livak KJ, Schmittgen T.D. (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method. Methods 25:402-408
23. Lorenzini CA, Baldi E, Bucherelli C., Sacchetti B, Tassoni G. (1996) Role of dorsal hippocampus in acquisition, consolidation and retrieval of rat's passive avoidance response: a tetrodotoxin functional inactivation study. Brain Res 730:32-39. doi:10.1016/0006-8993(96)00427-1
24. Luo K, Hong C, Liou Y., Hou S, Huang Y, Tsai S. (2010) Differential regulation of neurotrophin S100B and BDNF in two rat models of depression. Prog Neuro-Psychopharmacol Biol Psychiatry 34: 1433-1439
25. Miserendino MJ, Sananes CB, Melia K.R., Davis M. (1990) Blocking of acquisition but not expression of conditioned fear-potentiated startle by NMDA antagonists in the amygdala. Nature 345:716-718
26. Nestler EJ, Barrot M, DiLeone R.J., Eisch AJ, Gold SJ, Monteggia L.M. (2002) Neurobiology of depression. Neuron 34:13-25
27. Nowak G (1996) Calcium antagonists in the olfactory bulbectomy animal model of depression: Effect on the cortical NMDA receptor complex. Pol J Pharmacol 48:137-143
28. Orser B, Smith D, Henderson S., Gelb A. (1997) Magnesium deficiency increases ketamine sensitivity in rats. Can J Anaesth 44:883-890
29. Paoletti P, Neyton J, Ascher P. (1995) Glycine-independent and subunitspecific potentiation of NMDA responses by extracellular Mg2+. Neuron 15:1109-1120
30. Pochwat B, Szewczyk B, Sowa-Kucma M, Siwek A., Doboszewska U, Piekoszewski W, Gruca P., Papp M, Nowak G. (2014) Antidepressant-like activity of magnesium in the chronic mild stress model in rats: alterations in the NMDA receptor subunits. Int J Neuropsychopharmacol 17:393-405
31. Poleszak E, Szewczyk B, Kçdzierska E, Wlaź P, Pilc A, Nowak G (2004) Antidepressant-and anxiolyticlike activity of magnesium in mice. Pharmacology Biochemistry and Behavior 78:7-12
32. Poleszak E, Wlaź P, Kedzierska E, Nieoczym D, Wróbel A, Fidecka S, Pilc A, Nowak G (2007) NMDA/glutamate mechanism of antidepressant-like action of magnesium in forced swim test in mice. Pharmacol Biochem Behav 88:158-164
33. Poleszak E, Szewczyk B, Wlaź A, Fidecka S, Wlaź P, Pilc A, Nowak G (2008) D-serine, a selective glycine/N-methyl-D-aspartate receptor agonist, antagonizes the antidepressant-like effects of magnesium and zinc in mice. Pharmacol Rep 60:996-1000
34. Rihmer Z (2007) Suicide risk in mood disorders. Curr Opin Psychiatr 20: 17-22
35. Robichaud M, Beauchemin V, Lavoie N., Dennis T, Debonnel G. (2001) Effects of bilateral olfactory bulbectomy on N-methyl-D-aspartate receptor function: autoradiographic and behavioral studies in the rat. Synapse 42:95-103
36. Serefko A, Szopa A, Wlaz P., Nowak G, Radziwon-Zaleska M, Skalski M, Poleszak E. (2013) Magnesium in depression. Pharmacol Rep 65: 547-554
37. Singewald N, Sinner C, Hetzenauer A., Sartori SB, Murck H. (2004) Magnesium-deficient diet alters depression- and anxiety-related behavior in mice - influence of desipramine and Hypericum perforatum extract. Neuropharmacology 47:1189-1197
38. Slotnick BM (1973) Fear behavior and passive avoidance deficits in mice with amygdala lesions. Physiol Behav 11:717-720
39. Slutsky I, Abumaria N, Wu L., Huang C, Zhang L, Li B., Zhao X, Govindarajan A, Zhao M., Zhuo M, Tonegawa S, Liu G. (2010) Enhancement of learning and memory by elevating brain magnesium. Neuron 65:165-177. doi:10.1016/j.neuron.2009.12.026
40. Song C, Leonard B.E. (2005) The olfactory bulbectomised rat as a model of depression. Neurosci Biobehav Rev 29:627-647
41. Sowa-Kucma M., Szewczyk B, Sadlik K., Piekoszewski W, Trela F, Opoka W., Poleszak E, Pilc A, Nowak G. (2013) Zinc, magnesium and NMDA receptor alterations in the hippocampus of suicide victims. J Affect Disord 151:924-931. doi:10.1016/j.jad.2013.08. 009
42. Svenningsson P, Tzavara ET, Witkin J.M., Fienberg AA, Nomikos GG, Greengard P. (2002) Involvement of striatal and extrastriatal DARPP-32 in biochemical and behavioral effects of fluoxetine (Prozac). Proc Natl Acad Sci U S A 99:3182-3187
43. Svenningsson P, Bateup H, Qi H., Takamiya K, Huganir RL, Spedding M, Roth B.L., McEwen BS, Greengard P. (2007) Involvement of AMPA receptor phosphorylation in antidepressant actions with special reference to tianeptine. Eur J Neurosci 26:3509-3517
44. Szewczyk B, Pałucha-Poniewiera A, Poleszak E, Pilc A, Nowak G (2012) Investigational NMDA receptor modulators for depression. Expert Opin Investig Drugs 21:91-102. doi:10.1517/13543784.2012.638916
45. Van Hoomissen J.D., Chambliss HO, Holmes P.V., Dishman R.K. (2003) Effects of chronic exercise and imipramine on mRNA for BDNF after olfactory bulbectomy in rat. Brain Res 974:228-235
46. Van Riezen H., Leonard B.E. (1990) Effects of psychotropic drugs on the behavior and neurochemistry of olfactory bulbectomized rats. Pharmacol Ther 47:21-34
47. Zarate CA J.r., Singh JB, Carlson P.J., Brutsche NE, Ameli R, Luckenbaugh DA, Charney D.S., Manji H.K. (2006) A randomized trial of an Nmethyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 63:856-864
48. Zarate CA J.r., Brutsche NE, Ibrahim L, Franco-Chaves J, Diazgranados N., Cravchik A, Selter J, Marquardt C.A., Liberty V., Luckenbaugh D.A. (2012) Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biol Psychiatry 71:939-946